PBYI: Revenue and clinical momentum accelerate, with biomarker-driven trials advancing in 2026

NERLYNX continues to drive revenue growth, with raised guidance for 2026 and strong U.S. and international sales. Alisertib's phase II trials in breast and lung cancer show promising efficacy, especially in biomarker-defined subgroups, with expanded enrollment and further data expected in late 2026…